Tanya Lewis

Insider Reports History

Location
C/O Karyopharm Therapeutics Inc., 85 Wells Ave., Newton, MA
Signature
/s/ Scott Kellen, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Tanya Lewis:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Replimune Group, Inc. Chief Dev. Op. Officer Common Stock 135K $1.48M $10.92 Jun 13, 2023 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $3.69 Jun 1, 2025 Direct
DiaMedica Therapeutics Inc. Director Voting Common Shares, no par value per share 0 $0 $2.80 Jun 1, 2024 Direct
Replimune Group, Inc. Chief Dev. Op. Officer Employee Stock Option (right to buy) 60K Apr 1, 2023 Direct
DiaMedica Therapeutics Inc. Director Stock Option (right to buy) 32.2K Jun 1, 2025 Direct

Insider Reports Filed by Tanya Lewis

Symbol Company Period Transactions Value $ Form Type Date Filed Role
DMAC DiaMedica Therapeutics Inc. Jun 1, 2025 1 $0 4 Jun 3, 2025 Director
DMAC DiaMedica Therapeutics Inc. Jun 1, 2024 1 $0 4 Jun 3, 2024 Director
REPL Replimune Group, Inc. Jun 13, 2023 2 -$309K 4 Jun 15, 2023 Chief Dev. Op. Officer
DMAC DiaMedica Therapeutics Inc. Jun 1, 2023 1 $0 4 Jun 2, 2023 Director
REPL Replimune Group, Inc. May 16, 2023 1 -$220K 4 May 18, 2023 Chief Dev. Op. Officer
REPL Replimune Group, Inc. Apr 1, 2023 2 $0 4 Apr 4, 2023 Chief Dev. Op. Officer
DMAC DiaMedica Therapeutics Inc. Mar 1, 2023 1 $0 4 Mar 6, 2023 Director
DMAC DiaMedica Therapeutics Inc. Mar 1, 2023 0 $0 3 Mar 6, 2023 Director
REPL Replimune Group, Inc. May 16, 2022 1 -$79.9K 4 May 18, 2022 Chief Dev. Op Officer
REPL Replimune Group, Inc. Apr 1, 2022 2 $0 4 Apr 5, 2022 Chief Dev.Op Off
REPL Replimune Group, Inc. May 10, 2021 2 $0 4 May 11, 2021 Chief Dev. Oper. Off.